*Refresh the page if the below document does not appear.
Pharmaceutical company shares were in the spotlight as frontline stocks increased by up to 6% intraday on Monday as a result of a positive business outlook. Shares of Cipla reached a new high on the NSE of Rs 1,141.55, up 2%.
The US regulatory authority has granted an approval to Zydus Lifesciences US arm to manufacture the Generic version of ‘Mirabegron’ extended-release tablets of 25mg and 50mg with 180 days of shared generic drug exclusivity.
According to a recent notice, the National Pharmaceutical Pricing Authority, Ministry of Chemicals and Fertilizers, Government of India, has set the retail price of 40 drugs new including drugs indicated for the treatment of high blood pressure, type 2 diabetes, bacterial infection and so on.
The Department of Pharmaceuticals (DoP) and a qualified officer of the Union Health Ministry have been ordered by the Kerala High Court to submit their responses regarding the affordability of the life-saving patented breast cancer drug Ribociclib within a month.
On Saturday, Lupin Limited disclosed that its Ankleshwar manufacturing facility in Gujarat, India, had received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA).
Interesting trends are predicted for the Indian pharmaceutical industry in a recent Candle Partners report. The good news is that API manufacturing is finally getting the attention it deserves from promoters, private equity investors, and policymakers.
Leading pharmaceutical company USV Ltd.
has now lowered the price of its brand JalraOD in an effort to make its popular antidiabetic medication more accessible to the
Indian populace. The price has been reduced
from Rs 18 per tablet to Rs 13.5 per tablet.
If you don’t already have an account click the button below to create your account.Create New Account